BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Eyes Q2 Expansion of Growing Portfolio

Healthy Extracts (OTCQB: HYEX) recently released its full-year 2020 report. In addition to achieving a 71% jump in its revenue on the back of a plant-based industry boom, the company announced it was at an advanced stage of clinical testing that would culminate in the release of a new product in Q2 2021. The proprietary Fuel4Thought Brain Booster product will add to Health Extracts’ portfolio, which has increased thanks to acquisitions. An article on the developments reads, “Healthy Extracts acquired BergaMet NA in 2019, engaged in selling and distributing a full line of proprietary formulations derived from the rare Citrus Bergamot Superfruit(TM) (‘bergamot’) native to Southern Italy.” The company also acquired Ultimate Brain Nutrients, which “develops unique, plant-based superior proprietary neuro-brain solutions that enhance the brain’s overall health.”

To view the full article, visit https://ibn.fm/nVWiY

About Healthy Extracts Inc.

Healthy Extracts, through its two subsidiaries, BergaMet NA and Ultimate Brain Nutrients (“UBN”), is engaged in proprietary research and development of natural plant-based formulations, as well as sales and distribution of natural-ingredient cardiovascular and neuro products. For more information about the company, visit www.HealthyExtractsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Earth Science Tech, Inc. (OTC: ETST) Launches MyOnlineConsultation Platform Through MOCTeledoc 

Earth Science Tech (OTC: ETST) announced the official launch of MyOnlineConsultation.com through MOCTeledoc LLC, a fully integrated doctor…

10 hours ago

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress

NRx Pharmaceuticals (NASDAQ: NRXP) announced the filing of its Form 10-K for the year ended Dec.…

10 hours ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) To Present Deciparticle Platform And Pipeline At BIO-Europe Spring 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present its Deciparticle (TM)…

11 hours ago

BioMedNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Advances Anti-Drone Capabilities Through AFD Deployment Of Anduril Lattice Platform

Gaxos.ai (NASDAQ: GXAI) announced that its portfolio company, America First Defense (AFD), has begun deployment…

11 hours ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances Orphan Drug Strategy With HyBryte In Rare Skin Cancer

Soligenix (NASDAQ: SNGX) is advancing a differentiated approach to orphan drug development, emphasizing a de-risked model focused…

1 day ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting 

Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell lymphoma…

1 day ago